crodlifeoct 2009 presentation

QR SH 8.1.a 1

From Singapore and Australia to India. Cordlife now a part of your Life

Total Stem CellLifetime protection for your baby & family

Banking Solution

QR 8.1.1-1-8 2

What are stem cells ?Stem cells are body’s master/mother cells as they can differentiate into different types of cells to form organ systems of the body.

There are four accessible sources namely:• Bone marrow• Peripheral blood• Umbilical cord blood (UCB)• Umbilical cord tissue(Msc, EpSC)

UCB SC have a number of clear advantages over other stem cells:

• Reduced Ageing (Naïve)• Immunological Naivety- minimal GvHD• Ease of collection (safe, painless)

UCB can only be collected at the point of birthUCB can only be collected at the point of birthOne chance One ChoiceOne chance One Choice

AABB QR8.1.1.12_DCR198

Umbilical Cord Stem Cells (UCSCs)

Cord Blood consists of –

Cord Tissues consists of –

UCSCs have shown immense potential to treat diseases and repair injured tissues or organs

► Heart aliments / attack ► Cerebral Palsy Cerebral Palsy ► Stroke ► Leukaemia► Cartilage ► Breast Cancer► Healing of wounds especially that of diabetic ulcers

MSCs can also be used with cord blood stem cells to increase the success rate of cord blood transplants

• Hematopoietic stem cells (HSCs) • Mesenchymal stem cells (MSCs)• Unidentified stem cells (USCs)

• Mesenchymal stem cells (MSCs) • Epithelial stem cells (EpSCs)

Today, > 80 diseases officially Today, > 80 diseases officially recognisedrecognised as treatable as treatable diseases with cord blood stem cells, increasing each yeardiseases with cord blood stem cells, increasing each year


ØThe Only private Stem Cell bank in the world to have patented technology to isolate both mesenchymal stem cells (MSCs) epithelial stem cells (EpSCs)ØAll other banks can isolate only MSCs

Why choose Cordlife for umbilical cord stem cells banking?

CORDLIFECORDLIFE

More MSCs isolated than other banks

CORDLIFECORDLIFE

Two cells lines isolated


Technology that has been used in actual treatment – importance of EpSCs


Severe wounds from accidents, Gives tissues (flesh & Skins) growth


Diabetic sores , prevent patient’s limb-parts amputation

Cerebral PalsyCerebral Palsy(movement disorder)(movement disorder)

““OurOur sonson DallasDallas waswasdiagnoseddiagnosed atat 88 monthsmonths withwithcerebralcerebral palsy,palsy, aa typetype ofof brainbraininjuryinjury fromfrom birthbirth thatthat hashas nonoknownknown curecure.. (He)(He) waswas amongamongthethe firstfirst inin thethe [U[U..SS..]] toto bebeinfusedinfused withwith hishis ownown cordcordbloodblood stemstem cellscells.. Today,Today, …… heheruns,runs, hehe laughslaughs andand he'she'sbeginningbeginning toto talktalk..””

–– Derak and Cynthia Derak and Cynthia Hextell, founders of the Hextell, founders of the

Dallas Hextell Foundation Dallas Hextell Foundation (www.dallashextellfoundation.org)(www.dallashextellfoundation.org)

..

CordLife released a Client’s cord blood unit for Therapy in a child with Cerebral Palsy

Child was 2 ½ year old Georgia, who was diagnosed with Cerebral Palsy after birth. Her parents had chosen Cordlife and banked her cord blood with Cordlife at birth. A chance of live saving with stem cell therapy –Cordlife, One Chance One Choice

Brain RepairBrain Repair

¨̈2020--30 new child cases each year30 new child cases each year¨̈Trials in University of FloridaTrials in University of Florida¤¤Improved blood sugar controlImproved blood sugar control¤¤In certain cases, no longer need insulin injectionsIn certain cases, no longer need insulin injections

Type 1 DiabetesType 1 Diabetes

A leukaemia sufferer has become the first adult in the UK to undergo a bone marrow transplant using blood from a baby's umbilical cord.

Stephen Knox, 31, underwent the treatment - previously only performed on children - after being given just months to live.

The procedure was developed by Professor Stephen Proctor, who used stem cell blood from discarded placentas and umbilical cords.

Prof Proctor, based at Newcastle Hospital Trust's Haematology Unit and at Newcastle University, said Mr Knox had responded well to the transplant.

It's a really exciting development and opens up huge possibilities

Professor Stephen Proctor

The operation was carried out on Mr Knox, of Middleton-St-George, near Darlington, after various chemotherapy sessions failed to stem the leukaemia.

Mr Knox was given treatment to kill off his own bone marrow and then injected with the mixed cord blood that has grown into new bone marrow.

Mr Knox is in remission in hospital after undergoing the procedure in February.

Mr Proctor said: "This treatment was his only hope.

"Stephen is progressing much better than we thought he would and the transplant has worked much better and more quickly than we expected.

Cord Blood Transplant first for adult cancer patient

Monday, 8 July, 2002, UK

Mr. Akbar Ali in the press meet (In the centre with blue tops and pyjama)flanked by (From L.R) Dr JS Rajkumar (Chairman Life Line Hospital),Dr Narayanan (Neurosurgeon), Dr Ravikumar (Stem Cell Project Coordinator)Dr Baskaran (CEO, Life Line) Mr Yuji Okada (Consul, Consulate of Japan, Chennai),Dr Samuel JK Abraham (NCRM)

Source: National Geographic, July 2005

India's FIRST successful Stem Cell Therapy for Spinal Cord InjuryA press meet Jointly by Life Line Hospital & NCRM

A few points of scientific importance

Picture on the left shows the spinal cord compression (Yellow arrows) and vertebral bone damage (Red Arrows). Picture on the right was taken after the bones were fixed in a surgery using plates and screws.

About the cell source and their mechanism:In any such injury the damage is caused to the neural component and vascular component. The time within which the anatomical correction is undertaken (surgical fixing of the bones in this case) and adjunct therapies are started are very important. Earlier the treatment is given better could be the outcome.

About the cell source and their mechanism:

1. The cells used were NOT from any other source such as embryo or Umbilical cord blood or another human donor, but from his own bone marrow. Therefore this is safe.

2. The cells were not contaminated with any other biological material from human or animal origin.

3. The bone marrow stem cells do the repair in two ways: (i) Majority of the cells secrete trophic factors which help repair neural and vascular damages (ii) a small portion of the cells undergo fusion-differentiation to become nerve cells.

18

Manipal Hospital discovers cure for Parkinson`s disease (Apr. 04th., 2007)

Mr Andrew Kisana, a 58-year-old patient affected by Parkinson’s disease has shown positive signs of cure with stem cell therapy.

With the success in treating this patient, India-based Manipal Hospital has proved that stem cell therapy could be a potential option for easing out symptoms in a

patient suffering from Parkinson’s disease. Parkinson’s disease is a neuro-degenerative disease that affects people over the

age of 50.

Source:http://stemcell.taragana.net/archive/success-rate-of-stem-cell-therapy-in-india-is-encouraging/

Stem Cell Therapy: The Holy Grail of Medicine

Stem cell therapy is the new buzz in medical corridors with 'miracle' cures being reported everyday. Nancy Singh analyses the promises it holds for various diseases and the growing market for it.

Stem cell therapy is said to be expensive, however, considering that the effects of treatment are long lasting, without requiring expensive repetitive treatment, this seems affordable. Frost & Sullivan estimates that the annual cost of $2,500 per patient for SCT, at the manufacturer's level, is an average cost distributed over several years.

For large scale of production of stem cell lines, consistency is the key factor. Dr Mahendra Rao of Stem Cell Biology Unit, Gerontology Research Center, US, agrees, "Researchers must be able to repeat each other's experiments and establish a baseline set of quality controls that will be required for large scale therapy."

Four-month-old Aarohi Bhatt recently created medical history for being cured of a rare heart condition believed to be untreatable. The cause of her cure—Stem Cell Therapy (SCT) using her own blood at Frontier Lifeline Hospital, Chennai. Besides being a difficult surgery, it was for the first time in the world that SCT was successfully done on a child so young.

QR 8.1.1-1-8 20

Number of Diseases Treatable Number of Diseases Treatable with Cord Blood Stem Cells is Increasingwith Cord Blood Stem Cells is Increasing

Year 2000 & before 2002 – 2004 2006-Present

No. of cord blood therapies

Over 1,000(reported in 2000)

Over 2,500(Reported in Nov 2003)

Over 10,000(reported in Jun 2008)

No. of diseases treatable 46 74 82 recognised107 including ongoing

clinical trials

The Straits Times, July 1st 2004.Ryan Foo; 3 years old. Diagnosed with acute lymphoblastic leukemia (ALL) treated with younger sister’s sample stored with CordLife.18 months later: Leukemia in remission and Ryan has since started school.

Nature Biotechnology – A Global Authoritative Medical Journal

Cordlife group technology and A sample used in therapy as reported by international news & medical journals

QR 8.1.1-1-8 21

Malignant Diseases (Cancers)Leukaemia Neuroblastoma (Cancer of the nervous system)Lymphoma (Cancer of the lymph glands)Osteosarcoma (Bone Cancer)Wilms’ Tumour (Kidney Cancer)Breast Cancer

Today, > 80 diseases treatable Today, > 80 diseases treatable with cord blood stem cells, increasing with cord blood stem cells, increasing

each yeareach year

Non-Malignant DiseasesFanconi’s AnaemiaBubble Boy Disease (SCID)Sickle Cell Anaemia Aplastic AnaemiaThalassaemia (Major)Krabbe Disease

Clinical TrialsBrain TumourOvarian CancerLung CancerType 1 DiabetesCerebral Palsy

List of Applications for Stem Cell List of Applications for Stem Cell Transplantation and TherapyTransplantation and Therapy

QR 8.1.1-1-8 22

Factors important to the success of a Factors important to the success of a therapytherapy

• Human Leukocyte Antigen (HLA) matching between donor and recipient

• Post-therapy care to minimize chances of secondary infection

• Dose of stem cells received

– ↑cell dose, ↑therapy success / survival *Cell dose = number of nucleated cells per kg of body weight • X – Ray Wavier A Must

• Close proximity to facility• Secured collection kit

Every Cell Counts, Every degree of temperature & Every Minute - viability decreases

Cell Dose* Is The Single Most Important Factor.According To International Medical Standards, At Least 15 Million Cells Per Kg Is Required Before Anytherapy Is Attempted.


Technology are internationally patented in various countries including India and Europe. This technology is used only by Cordlife

CordLife India is a subsidiary of the Cordlife GroupThe First Foreign owned and operated stem cell bank in India

CordLife group is a Public listed company on the mainboard of the AustralianSecurities Exchange (www.asx.com.au Ticker code CBB)

• Has the most number of stem cell banking facilities in the world todaysince 2001

• The group has no franchises/“technical collaboration” or distributorsSame promoter /owner from Singapore to Australia now in India

• All facilities are designed; built & operated by technical teams fromSingapore & Australia. Facility managed by Medical Doctor


Profile of Cord

QR 8.1.1-1-8 26

• Designed to customised requirements by Technical teams from Singapore, United States and Australia

• Storage set up with multiple fail-safe systems , • Fire-retardant walls

• 365 days backup system, 24-hour emergency • power supply

• Connected to back-up power generator

• Can remain at optimal Temperature for over 2 weeks with no power required

• Storage facility can hold up to 30,000 scalable up to a few lac units

• Controlled access to the laboratory

Make an appointment to view our state-of-the-art laboratory!

Secured Facility Secured Facility ––Designed for the future, serving you Designed for the future, serving you todaytoday

India

Singapore Hong Kong

QR 8.1.1-1-8 27

• Release of Cord Blood to over102 patients* from inception

• Till date units released have been used to treat over 18 indications at over 28 institutions globally*

• Increasing number of units released as cord blood applications increase

Blood Cancers

85%

Genetic Disease

9%

Cell Therapy

6%

*Data derived from CordLife and Partners International Facilities

Cordlife international therapy Cordlife international therapy track recordtrack record

0

5

10

15

20

25

30

35

40

2000 2001 2002 2003 2004 2005 2006 2007 2008*Data derived from CordLife Group and Associates

QR 8.1.1-1-8 28

Therapy Centre City Location

AIIMS New Delhi IndiaApollo Speciality Hospital Chennai IndiaChan Gung Children Hospital Taipei TaiwanDana Farber Cancer Centre Boston USADharmais National Cancer Centre Jakarta IndonesiaDuke University Medical Centre Durham USAErasmus Medical Centre Rotterdam NetherlandsFred Hutchinson Cancer Centre Seattle USAHospital Saint Louis Paris FranceInstitute Gustave Roussy Villejuif FranceKanagawa Cancer Centre Japan KanagawaKarolinska University Hospital Stockholm SwedenKK Women and Children's Hospital Singapore SingaporeMassachusetts General Hospital Boston USAMD Anderson Medical Centre Houston USAMount Elizabeth Hospital Singapore SingaporeMt Sinai Medical Centre New York USANational Taiwan Hospital Taipei TaiwanQueen Mary Hong Kong Hong KongRoyal Marsden Hospital London UKSamitivej Hospital Bangkok ThailandSheffiled Children Hospital Sheffiled UKSir Ganga Ram Hospital New Delhi IndiaSloan Kettering Cancer Centre New York USAUniversity of Malaya Medical Centre Kuala Lumpur Malaysia

With 10 years of experience, Cordlife is the only trusted With 10 years of experience, Cordlife is the only trusted international bank able to coordinate therapies at renowned international bank able to coordinate therapies at renowned centrescentres in India and globally:in India and globally:

We know how: who: where: to receive We know how: who: where: to receive best quality stem cell therapiesbest quality stem cell therapies

Cordlife international therapy networkCordlife international therapy network

QR 8.1.1-1-8 29

Cordlife Banking ExcellenceCordlife Banking ExcellenceCordlife manages100% of all Cordlife companies and operations in Australasian region with latest technology available to the Indian laboratory – no franchise, no gimmicks, no foreign collaborators because we are the international direct promoters

AABB

ISO TGA Singapore Ministry of Health

Indonesia Ministry of Health

India Ministry of Health and

Family Welfare of India

Cordlife group companies are recognised by AABB, TGA and various government health authorities. Cordlife is also the official consultant to the Singapore government for its public stem cell bank in 2004 and partner for the Healthcare blueprint development in Valkenburg, Holland

Former Prime Minister of Singapore, His Excellency, Mr Goh Chok Tong, graced Cordlife India launch at Taj Bengal, 2005

QR 8.1.1-1-8 30

Cordlife Banking Excellence Cordlife Banking Excellence --WEFWEFOur 10 years of experience and propriety technology has attained the highest honour of global recognition by Geneva based WEF - Cordlife service is now available in India

QR 8.1.1-1-8 31

CordLife India pride our adherence to best international practices. In addition to AABB standards (America), FACT-Netcord standards (Europe) and

Therapeutic Goods Administration (Australia).We are now ISO 9001:2008 certified in India, the latest edition of ISO from 2008.

Licensed by the Drug Controller General of India, (DCGI) to process andstore human progenitor cell-cord, CordLife strives for the highest standardsin meeting our vision:

cordlife is to date the only company in India that complies to thestandards set by the American Association of Tissue Banks for umbilical cordtissue banking.


Another important question to ask: What are the Charges?

Affordable…….•Various Flexible payment plans available with as low as Rs1,900with as low as Rs1,900•18years + 3 years free from 193 years free from 19thth to 21to 21stst

•Refer-A-Friend – Get Rs 3,600 when your friend signs upGet Rs 3,600 when your friend signs upCommitted to help and protect……….

•Free medical concierge in the world- A COMMITMENTA COMMITMENT•Free transportation to anywhere in the world- A GUARANTEEA GUARANTEE

Cordlife Pricing Plans

Limited period offer:- Storage fee for cord tissues waved for 21 yearsYearly Payment Plan Flexi 24 Flexi 12 Annual

Enrolment 5,000 5,000 5,000 Processing 1,700 x 24 mths 3,150 x 12 mths 37,000 Storage fee* 3,600 3,600 3,600

*(Storage fee payable every year)

18 years One-time payment Flexi 18-24 Flexi 18-12 18 yearsEnrolment 5,000 5,000 5,000

Processing & Storage 3,300 x 24 mths 6,100 x12 mths 72,000

QR 8.1.1-1-8 33

“…“…CordLife shall at its own cost, seek a Cord Blood Unit of a suitable Human Leukocyte CordLife shall at its own cost, seek a Cord Blood Unit of a suitable Human Leukocyte Antigen (“Antigen (“HLAHLA”) match to the cord blood donor………..”) match to the cord blood donor………..

…If CordLife fails to obtain a Cord Blood Unit of a suitable …If CordLife fails to obtain a Cord Blood Unit of a suitable HLAHLA match, the amount of match, the amount of damages that you may recover from CordLife shall …be……damages that you may recover from CordLife shall …be……

…”…”* For the Full Clause, please refer to Cord Blood Banking Service Agreement.* For the Full Clause, please refer to Cord Blood Banking Service Agreement.

The The ONLYONLY Cord Blood Bank in India and Asia to offer a Cord Blood Bank in India and Asia to offer a legally binding guarantee as stated in the Agreement for legally binding guarantee as stated in the Agreement for

your child’s precious cord bloodyour child’s precious cord blood

Cordlife Quality WarrantyCordlife Quality Warranty

Not just about certifications, we hold our quality, our Not just about certifications, we hold our quality, our promise as good as promise as good as in our contractin our contract

QR 8.1.1-1-8 34

Question and AnswersQuestion and Answers

crodlifeoct 2009 presentation

Documents